Dr. Robert Huizinga reports

KANE BIOTECH ANNOUNCES GRANT OF STOCK OPTIONS

On May 28, 2026, Kane Biotech Inc. granted an aggregate of 9.75 million stock options to certain directors, officers, employees and consultants of the company in accordance with the company's third amended and restated stock option plan.

Each option is exercisable into one common share of the company at a price of five cents per share, for a period of five years from the date of grant. The options will vest over six months, with half vesting immediately and one-12th vesting for the next six months after the date of the grant.

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve anti-microbial wound gel, revyve anti-microbial wound gel spray, and revyve anti-microbial skin and wound cleanser are all U.S. Food and Drug Administration 510(k) cleared. revyve anti-microbial wound gel and revyve anti-microbial wound gel spray are also Health Canada approved.

We seek Safe Harbor.